Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Catalio Capital Management
Portfolio Companies: Catalio
eGenesis

Organization & Developments: Egenesis

Parents

*Developer of human-compatible engineered organs and cells
*Focused on shortage of transplantable organs.
*Provides genome-engineering platform that inactivates porcine retroviruses, inserts human genes, and edits multiple immune-rejection pathways to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases
2025: First clinical trial of pig kidney transplants gets underway
2025: Scientists Grow More Hopeful About Ending a Global Organ Shortage
2026: Transplanted Pig Kidney Still Working After a Record-Setting 9 Months in a Patient | WIRED
eGenesis is a gene editing company founded by Dr. George Church at Harvard Medical School, developing xenographic organs for transplantation in humans.